Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Poseida Therapeutics Inc (PSTX)

Poseida Therapeutics Inc (PSTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 736,276
  • Shares Outstanding, K 61,820
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,530 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.12
Trade PSTX with:

Options Overview

Details
  • Implied Volatility 130.04%
  • Historical Volatility 81.31%
  • IV Percentile 5%
  • IV Rank 2.05%
  • IV High 890.32% on 01/22/21
  • IV Low 114.17% on 02/25/21
  • Put/Call Vol Ratio 1.00
  • Today's Volume 22
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 814
  • Open Int (30-Day) 232

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.69
  • Number of Estimates 3
  • High Estimate -0.59
  • Low Estimate -0.75
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.41 +31.27%
on 01/28/21
13.64 -19.06%
on 02/24/21
+2.20 (+24.89%)
since 01/26/21
3-Month
8.40 +31.43%
on 01/14/21
13.98 -21.03%
on 12/28/20
-0.42 (-3.66%)
since 11/25/20

Most Recent Stories

More News
Poseida Therapeutics Provides Update on Key Programs and Developments During R&D Day

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics to Host Virtual R&D Day on February 24, 2021

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics to Participate in SternIR Virtual Corporate Access Event

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics Added to NASDAQ Biotechnology Index

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
IBB : 156.93 (-0.14%)
Poseida Therapeutics Appoints Luke Corning to Board of Directors

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics Provides Update on Phase 1 Trial of P-BCMA-101 at the 2020 American Society of Hematology Annual Meeting

, /PRNewswire/ -- Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics Reports Operational Update and Financial Results for Third Quarter 2020

, /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous CAR-T Study in Prostate Cancer

, /PRNewswire/ -- Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary gene engineering platform technologies to create next generation...

PSTX : 11.04 (-7.30%)
Poseida Therapeutics and TScan Therapeutics Announce Research Collaboration and License Agreement to Explore Developing Allogeneic T Cell Receptor Therapies for the Treatment of COVID-19

and , /PRNewswire/ --Poseida Therapeutics, Inc. (NASDAQ:PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics...

PSTX : 11.04 (-7.30%)

Business Summary

Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed...

See More

Key Turning Points

3rd Resistance Point 13.82
2nd Resistance Point 13.16
1st Resistance Point 12.10
Last Price 11.04
1st Support Level 10.38
2nd Support Level 9.72
3rd Support Level 8.66

See More

52-Week High 17.62
Fibonacci 61.8% 13.80
Fibonacci 50% 12.63
Fibonacci 38.2% 11.45
Last Price 11.04
52-Week Low 7.63

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar